Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.
INTRODUCTION: Apremilast is approved for the treatment of psoriasis and psoriatic arthritis (PsA). Real-world evidence on the efficacy and safety of apremilast in clinical practice is limited. We assessed the use of apremilast in patients with PsA in Belgium clinical practice. METHODS: The multicentre, observational, prospective APOLO study enrolled patients with active PsA initiating apremilast in Belgium between April 2017 and December 2018. Primary outcome was PsA Response Criteria (PsARC) after 6 months of apremilast treatment. Secondary outcomes included PsA Impact of Disease 12 (PsAID12)... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Verlag/Hrsg.: |
Springer Healthcare Communications
|
Schlagwörter: | Anti-Inflammatory Agents / Non-Steroidal / Arthritis / Psoriatic / Belgium / Humans / Prospective Studies / Quality of Life / Thalidomide / Treatment Outcome / Apremilast / Patient-reported outcome / Psoriatic arthritis / Real-world evidence |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28493553 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/263799 |